24 March 2016
Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
The prognostic importance of lung diffusion capacity testing in pulmonary hypertension patients has been analysed in this study published in the Journal of the American College of Cardiology
This study sought to investigate the prognostic importance of a low diffusion capacity of the lung for carbon monoxide (DLCO) in patients with a catheter-based diagnosis of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).
The study findings show that "in patients with PH-HFpEF, a low DLCO is associated with a high mortality risk.
The article details are the following:
- Title: "Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction"
- Authors: Marius M. Hoeper, Katrin Meyer, Jessica Rademacher, Jan Fuge, Tobias Welte, Karen M. Olsson
- Published in:Journal of the American College of Cardiology (JACC Heart Failure) February 2016
The scientific article can be purchased at the following link: click here
Founded in 1980, COSMED is a privately owned company manufacturing Cardio Pulmonary and Metabolic Diagnostic Equipment. COSMED products include a full range of Spirometers, Pulmonary Function, Body Composition, Nutritional Assessment and Cardio Pulmonary Exercise systems, including Electrocardiographs, Ergometers and Assessment Software. COSMED solutions are aimed for either professional or medical use for many different applications like: Hospital, Clinics, Primary Care, University & Education in Human Physiology, Clinical Nutrition, Commercial Weight Management, Human Performance Centers, Sport Institutions and Health Club Industry. COSMED Headquarters are located in the province of Rome, Italy. COSMED has subsidiaries in the USA, China and Germany, and distributes its products internationally through a constantly growing distributor network covering more than 70 countries.